Therapeutic combinations of RAR antagonists and RXR agonists and use thereof

US6653322B1 · kind B1 · utility

Assignees

• Bristol-Myers Squibb Company · US
• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
• UNIVERSITE LOUIS PASTEUR · FR

Inventors

• Pierre Chambon · Blaesheim, FR
• Hinrich Gronemeyer · Oberkirch, DE
• Peter R. Reczek · East Amherst, US
• Jacek Ostrowski · Lompoc, US

Key dates

• Filing date: Jul 19, 2000
• Grant date: Nov 25, 2003
• Expiry date: Aug 20, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compositions and methods for treating an animal, preferably a human, suffering from or predisposed to a physical disorder by administering an effective amount of a composition comprising at least one RAR antagonist, preferably an RAR&agr; antagonist, and at least one RXR agonist. The combination of an RXR agonist, which has no therapeutic effects alone, with an RAR antagonist allows the use of lower doses of the RAR antagonist than were previously thought to be efficacious; this approach obviates many of the undesirable physiological side-effects of treatment with RAR antagonists.